NORA BOLANOS: Open Payments
NPI 1578964177 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,447 in 53 payments from 25 companies in 2025. Trend: 2023 $255 · 2024 $0 · 2025 $1,447
Food & beverage: $1,173Education: $274
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 9 | $233 |
| Merck Sharp & Dohme LLC | 8 | $189 |
| Stemline Therapeutics Inc. | 2 | $142 |
| GlaxoSmithKline, LLC. | 1 | $109 |
| Gilead Sciences, Inc. | 1 | $100 |
| SEAGEN INC. | 1 | $75 |
| AstraZeneca Pharmaceuticals LP | 3 | $61 |
| GENZYME CORPORATION | 3 | $58 |
| TerSera Therapeutics LLC | 3 | $57 |
| Regeneron Healthcare Solutions, Inc. | 2 | $56 |
Products named: KEYTRUDA, Orserdu, RYBREVANT, OJJAARA, Trodelvy, TALVEY, SARCLISA, Zoladex.
Industry payments across TX — which companies pay providers there.
